TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06804824: A First-in-Human (FIH) Study to Evaluate the Safety and Tolerability of VVD-159642 in Participants With Advanced Solid Tumors

Sponsor: Vividion Therapeutics, Inc. · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 220 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06804824 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06804824 Rescue Dossier →